Clinical Effect of Tislelizumab Combined with Chemotherapy in the Treatment of Stage IIIb–IV Non-Small Cell Lung Cancer

Abstract

Objective: To analyze the therapeutic effect of tislelizumab combined with chemotherapy in patients with stage IIIb–IV non-small cell lung cancer (NSCLC). Methods: A total of 50 patients with stage IIIb–IV NSCLC admitted between January 2022 and January 2024 were randomly divided into two groups using a random number table. The observation group included 25 cases treated with tislelizumab combined with chemotherapy, while the reference group included 25 cases treated with conventional chemotherapy. The clinical control rate, adverse reaction rate, tumor markers, immune function indicators, and quality of life scores were compared between the two groups. Results: The observation group had a higher clinical control rate and a lower adverse reaction rate compared to the reference group (P < 0.05). Before treatment, there were no significant differences in tumor markers, immune function indicators, and quality of life scores between the two groups (P > 0.05). Three months after treatment, the tumor marker levels in the observation group were lower than those in the reference group. Except for CD8+, all immune function indicators in the observation group were higher than those in the reference group, and the quality-of-life scores in the observation group were higher than those in the reference group (P < 0.05). Conclusion: Implementing tislelizumab combined with chemotherapy in patients with stage IIIb–IV NSCLC can improve the clinical control rate, reduce the adverse reaction rate, lower tumor marker levels, protect immune function, and improve quality of life.